Safety of Ferric Carboxymaltose Immediately after Infliximab Administration, in a Single Session, in Inflammatory Bowel Disease Patients with Iron Deficiency: A Pilot Study

European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases

(2015) Axel U Dignass et al.   Journal of Crohns & Colitis

Ferric Carboxymaltose: A Review of Its Use in Iron Deficiency

(2014) Gillian M. Keating   DRUGS

Prevalence of Anemia in Inflammatory Bowel Diseases in European Countries

(2014) Natalie Filmann et al.   INFLAMMATORY BOWEL DISEASES

Treatment of Anemia in Inflammatory Bowel Disease– Systematic Review and Meta-Analysis

(2013) Tomer Avni et al.   PLoS One

Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life

(2013) Ragnar Befrits et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Cost-Minimization Analysis Favours Intravenous Ferric Carboxymaltose over Ferric Sucrose for the Ambulatory Treatment of Severe Iron Deficiency

(2012) Xavier Calvet et al.   PLoS One

FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease

(2011) Rayko Evstatiev et al.   GASTROENTEROLOGY

Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: A systematic review and meta-analysis

(2011) Thomas W. Lee et al.   Journal of Crohns & Colitis

Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-  treatment

(2009) G. Bergamaschi et al.   HAEMATOLOGICA

A Novel Intravenous Iron Formulation for Treatment of Anemia in Inflammatory Bowel Disease: The Ferric Carboxymaltose (FERINJECT®) Randomized Controlled Trial

(2008) Stefanie Kulnigg et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY